63 Investor presentation Full year 2022 Patient access to anti-obesity me the US and IO The~40 million people having access to Wegovy ® is nearly the number of people with diabetes in the US (~50 million) ~110m Obesity prevalence in US adults 1 ~60m Commercial Channel • ~80% formulary access • ~50% of employers opt-in ~30m People with commercial coverage ~10m Medicaid 2 Note: Obesity is defined as BMI > 30. 1 Prevalence: Adult obesity facts. Centers for Disease Control and Prevention, https://www.cdc.gov/obesity/data/adult.html; US Cens 2 Also includes DoD and government employees
Download PDF file